Therapeutic area intelligence for Cognitive Impairment with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 3
Catalysts: 0
Companies: 0

Companies

No related entities indexed yet.

Assets

Lavender →

Riluzole →

Recent signals(3)

ClinicalJuly 19, 2026

Lavender Aromatherapy Trial for Cognitive Function in Older Adults with MCI

A clinical trial is underway to evaluate the effects of lavender aromatherapy on cognitive function in older adults with Mild Cognitive Impairment.

ClinicalJuly 17, 2026

Phase 2a Trial of Riluzole for Cancer-Related Cognitive Impairment Initiated

A phase 2a pilot trial is underway to assess riluzole's effects on BDNF levels in cancer survivors with cognitive impairment.

ClinicalJuly 6, 2026

Study on Semiconductor Headbands for Cognitive Impairment in Cancer Patients

A clinical trial is investigating the feasibility and effectiveness of semiconductor embedded headbands for cognitive impairment in breast and gynecological cancer patients.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.